Impact of modification of the standard intraperitoneal paclitaxel/cisplatin chemotherapy regimen on progression-free survival

被引：0
|
作者：
Lesnock, J. [1 ]
Chu, T. [1 ]
Richard, S. [2 ]
Kubenik, M. [1 ]
Krivak, T. [1 ]
Zorn, K. [1 ]
Sukumvanich, P. [1 ]
Kelley, J. [1 ]
Edwards, R. [1 ]
机构：
[1] Univ Pittsburgh, Magee Womens Hosp, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Magee Womens Hosp, Wexford, PA USA
来源：
GYNECOLOGIC ONCOLOGY | 2010年 / 116卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
349
引用
收藏
页码：S136 / S136
页数：1
相关论文
共 50 条
  • [31] THE IMPACT OF AGGRESSIVE DEBULKING SURGERY AND CISPLATIN-BASED CHEMOTHERAPY ON PROGRESSION-FREE SURVIVAL IN STAGE-III AND STAGE-IV OVARIAN-CARCINOMA
    PIVER, MS
    LELE, SB
    MARCHETTI, DL
    BAKER, TR
    TSUKADA, Y
    EMRICH, LJ
    JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (06) : 983 - 989
  • [32] IMPACT OF EARLY LYMPHOCYTE RECOVERY ON PROGRESSION-FREE AND OVERALL SURVIVAL IN OSTEOSARCOMA
    Lee, Lynn
    Fei, Lin
    Pope, Jennifer
    Wagner, Lars
    PEDIATRIC BLOOD & CANCER, 2013, 60 : S70 - S71
  • [33] The Impact of Focal Lesions on Overall and Progression-free Survival in Multiple Myeloma
    Kirkizlar, Tugcan Alp
    Kirkizlar, Onur
    Soyluoglu, Selin
    Umit, Elif Gulsum
    Ustun, Funda
    Demir, Ahmet Muzaffer
    INDIAN JOURNAL OF NUCLEAR MEDICINE, 2024, 39 (05): : 353 - 359
  • [34] Impact of tumour volume on prediction of progression-free survival in sinonasal cancer
    Hennersdorf, Florian
    Mauz, Paul-Stefan
    Adam, Patrick
    Welz, Stefan
    Sievert, Anne
    Ernemann, Ulrike
    Bisdas, Sotirios
    RADIOLOGY AND ONCOLOGY, 2015, 49 (03) : 286 - 290
  • [35] Phase II study of intravenous bevacizumab (bev) and paclitaxel (pac), and intraperitoneal (ip) cisplatin (c), followed by bevacizumab (bev) maintenance, for advanced ovarian cancer: A report on progression-free survival (PFS) and toxicity
    Perry, L.
    Lanneau, G.
    Curiel, J.
    Mathews, C.
    Moxley, K.
    Landrum, L.
    Moore, K.
    Walker, J.
    Mannel, R.
    McMeekin, D.
    GYNECOLOGIC ONCOLOGY, 2012, 125 : S22 - S22
  • [36] ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy
    Johnatty, Sharon E.
    Beesley, Jonathan
    Paul, Jim
    Fereday, Sian
    Spurdle, Amanda B.
    Webb, Penelope M.
    Byth, Karen
    Marsh, Sharon
    McLeod, Howard
    Harnett, Paul R.
    Brown, Robert
    de Fazio, Anna
    Chenevix-Trench, Georgia
    CLINICAL CANCER RESEARCH, 2008, 14 (17) : 5594 - 5601
  • [37] Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
    Loek A. W. de Jong
    Marie Lambert
    Nielka P. van Erp
    Lukas de Vries
    Etienne Chatelut
    Petronella B. Ottevanger
    Cancer Chemotherapy and Pharmacology, 2023, 91 : 247 - 256
  • [38] Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
    de Jong, Loek A. W.
    Lambert, Marie
    van Erp, Nielka P.
    de Vries, Lukas
    Chatelut, Etienne
    Ottevanger, Petronella B.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 91 (03) : 247 - 256
  • [39] PROGRESSION-FREE AND SURVIVAL RATE OF CHEMOTHERAPY IN PEDIATRICS WITH OPTIC PATHWAY GLIOMAS: A SYSTEMATIC REVIEW
    Pangaribuan, Vega
    Kurniawan, Jemmy
    Widyandana, Doni
    NEURO-ONCOLOGY, 2020, 22 : 137 - 137
  • [40] Efficacy of the Nordic and the MSKCC chemotherapy protocols on the overall and progression-free survival in intracranial PCNSL
    Da Broi, Michele
    Jahr, Guro
    Beiske, Klaus
    Holte, Harald
    Meling, Torstein R.
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 73 : 25 - 32
12345